Monopar Therapeutics Inc (MNPR)

Monopar Therapeutics' stock has experienced fluctuations, with a latest closing price of $56.88 as of early February 2026. Over the last 12 months, the stock's price increased by 148.52%, but in the past month (as of January 2026), it decreased by 15.56%. A 1-5 reverse stock split occurred on August 13th, 2024. On November 13, 2025, Monopar Therapeutics reported its Third Quarter 2025 financial results, with an earnings per share (EPS) of ($0.48), missing the consensus estimate of ($0.46). Insider selling activity has contributed to a stock price decrease.

The demand for Monopar Therapeutics' products and services is not subject to typical seasonal fluctuations. Demand is primarily driven by the progress of its clinical trials, regulatory milestones, and the eventual commercialization of its drug candidates.

Monopar Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for cancer patients and Wilson Disease. The company's pipeline includes radiopharmaceuticals targeting advanced solid tumors and ALXN1840 for Wilson Disease. Monopar develops Camsirubicin, an analog of doxorubicin, and MNPR-202 for drug-resistant cancers, building its pipeline through in-house efforts and licensing therapeutics.

Monopar Therapeutics, Inc. is headquartered in Wilmette, Illinois, with its team located in Chicago, IL. The company develops therapeutics for cancer patients in the United States, with clinical trials for MNPR-101 active in Australia as of August 2025. Monopar Therapeutics also has subsidiaries, including Monopar Therapeutics Pty Ltd and Monopar Therapeutics SARL.

Monopar Therapeutics has a generally positive brand reputation among analysts, holding a consensus "Buy" rating. The company's average analyst rating score is 3.00. MarketBeat evaluated Monopar Therapeutics, scoring it higher than 67% of companies in the medical sector. While the company missed its Q3 2025 EPS estimates, this financial event is primarily reflected in stock performance rather than a broad negative impact on its overall brand reputation.

Monopar Therapeutics Inc. has 108 institutional owners and shareholders holding a total of 4,591,464 shares. Major institutional owners include Janus Henderson Group Plc, Adage Capital Partners Gp, L.l.c., Ra Capital Management, L.p., Vanguard Group Inc, Wellington Management Group Llp, BlackRock, Inc., Deerfield Management Company, L.p. (series C), Saturn V Capital Management LLC, TCG Crossover Management, LLC, ADAR1 Capital Management, LLC, AstraZeneca PLC, and State Street Corp. Individual insiders who own company stock include Tactic Pharma Llc, Chandler Robinson, Andrew Cittadine, Kim R Tsuchimoto, Christopher M Starr, and Karthik Radhakrishnan.